Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Change in Receivables (2021 - 2023)

Inhibikase Therapeutics (IKT) has disclosed Change in Receivables for 3 consecutive years, with -$79602.0 as the latest value for Q3 2023.

  • On a quarterly basis, Change in Receivables fell 1191.93% to -$79602.0 in Q3 2023 year-over-year; TTM through Jun 2024 was -$79602.0, a 143.45% decrease, with the full-year FY2023 number at -$39881.0, down 200.0% from a year prior.
  • Change in Receivables was -$79602.0 for Q3 2023 at Inhibikase Therapeutics, down from $15083.0 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $332774.0 in Q1 2021 to a low of -$369099.0 in Q3 2021.
  • A 3-year average of $10012.8 and a median of $7290.0 in 2022 define the central range for Change in Receivables.
  • Peak YoY movement for Change in Receivables: surged 226.87% in 2022, then plummeted 1191.93% in 2023.
  • Inhibikase Therapeutics' Change in Receivables stood at -$107341.0 in 2021, then soared by 226.87% to $136180.0 in 2022, then plummeted by 158.45% to -$79602.0 in 2023.
  • Per Business Quant, the three most recent readings for IKT's Change in Receivables are -$79602.0 (Q3 2023), $15083.0 (Q2 2023), and $24638.0 (Q1 2023).